Allergy/Imm Medical News about vaccination

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations
Cancer Immunology, Immunotherapy, 09/23/09

Boehm AL et al. – Concurrent administration of two vaccines targeting the same antigen induces a more diverse T–cell population that leads to enhanced antitumor efficacy. These studies provide the rationale for future clinical studies investigating concurrent administration of vaccine platforms targeting a single antigen to enhance the antigen–specific immune response.

Exclusive Author Commentary
Amanda Boehm, 09/28/09

Commentary for “Concurrent vaccination with two distinct vaccine platforms targeting the same tumor antigen generates phenotypically and functionally distinct T-cell populations” by A. L. Boehm, et al. 2009. Cancer Immune Immunother. Combination therapy is not a new concept for the treatment of cancer. For years, oncologists have combined multiple chemotherapeutic drugs to achieve the maximum therapeutic efficacy. The first FDA-approved therapeutic cancer vaccine is expected to be approved at the end of this year, and several other therapeutic cancer vaccines are in the late stages of development. It is foreseeable multiple cancer vaccines could be combined to target a single tumor-associated antigen. Our study is the first to show that two vaccine platforms targeting the same antigen can be concurrently administered due to their induction of distinct T-cell populations. Furthermore, our data show that this combination of therapeutic vaccines results in significantly increased antitumor effects in vivo, setting the stage for future studies employing combination therapy for cancer with two vaccines targeting the same tumor-associated antigen.

<< Previous
Social support and delays seeking care after HIV diagnosis, North...

Next >>
Prognostic value of CD208-positive cell infiltration in gastric...